The Technical Analyst
X4 Pharmaceuticals Inc [XFOR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
X4 Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
4.88% $1.290
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 216.64 mill |
| EPS: | -0.570 |
| P/E: | -2.26 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 167.94 mill |
| Avg Daily Volume: | 2.44 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | n/a | |||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.26 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.38x |
| Company: PE -2.26 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.232 (-82.04%) $-1.058 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.168 - 1.412 ( +/- 9.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-11 | Taveras Arthur | Sell | 14 235 | Common Stock |
| 2024-03-11 | Ragan Paula | Sell | 49 678 | Common Stock |
| 2024-03-11 | Mostafa Adam S. | Sell | 52 500 | Common Stock |
| 2024-03-11 | Dibiase Mary | Sell | 15 409 | Common Stock |
| 2024-02-13 | Arbet-engels Christophe | Buy | 180 816 | Stock Appreciation Right |
| INSIDER POWER |
|---|
| 80.30 |
| Last 96 transactions |
| Buy: 15 169 198 | Sell: 1 336 024 |
Forecast:
16:00 - $1.290
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.290
Forecast 2: 16:00 - $1.290
Forecast 3: 16:00 - $1.290
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.290 (4.88% ) |
| Volume | 1.709 mill |
| Avg. Vol. | 2.44 mill |
| % of Avg. Vol | 70.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XFOR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.864 | N/A | Active |
|---|
XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-04-02 16:05:00 - Press Release
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing rule 5635(c)(4)
Boston, april 02, 2024 (globe newswire) -- x4 pharmaceuticals (nasdaq: xfor), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on april 1, 2024, the company issued inducement awards to new employees under the x4 pharmaceuticals, inc. 2019 inducement equity incentive plan (the “2019 inducement plan”). the 2019 inducement plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of x4. the inducement awards consist of options to purchase an aggregate of 1,164,470 shares of x4's common stock. these stock awards were granted as an inducement material to the new employees entering into employment with x4 in accordance with nasdaq listing rule 5635(c)(4) and were approved by x4's compensation committee of the board of directors.
2024-04-01 08:00:00 - Press Release
X4 Pharmaceuticals To Participate In Upcoming April Investor Conferences
Boston, april 01, 2024 (globe newswire) -- x4 pharmaceuticals (nasdaq: xfor), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming needham 23rd annual healthcare conference being held virtually from april 8-11, 2024, and the piper sandler spring biopharma symposium being held in boston from april 16-17, 2024.
2024-03-21 06:01:00 - Press Release
X4 Pharmaceuticals Reports Fourth-quarter And Full-year 2023 Financial Results And Provides Corporate Update
Launch preparations underway in anticipation of possible u.s. approval of mavorixafor for whim syndrome; u.s. pdufa target action date set for april 30, 2024
2024-03-12 08:00:00 - Press Release
X4 Pharmaceuticals To Report Fourth-quarter And Full Year 2023 Financial Results And Host A Conference Call And Webcast On March 21, 2024
Boston, march 12, 2024 (globe newswire) -- x4 pharmaceuticals, inc. (nasdaq: xfor), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended december 31, 2023 and providing corporate updates on thursday, march 21, 2024.
2024-03-01 16:05:00 - Press Release
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing rule 5635(c)(4)
Boston, march 01, 2024 (globe newswire) -- x4 pharmaceuticals (nasdaq: xfor), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on february 29, 2024, the company issued inducement awards to new employees under the x4 pharmaceuticals, inc. 2019 inducement equity incentive plan (the “2019 inducement plan”). the 2019 inducement plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of x4. the inducement awards consist of options to purchase an aggregate of 1,524,112 shares of x4's common stock. these stock awards were granted as an inducement material to the new employees entering into employment with x4 in accordance with nasdaq listing rule 5635(c)(4) and were approved by x4's compensation committee of the board of directors.
Latest News
2024-04-01 08:00:00 - GlobeNewsWire
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.
2024-03-12 08:00:00 - GlobeNewsWire
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.
2023-12-13 23:43:55 - Seeking Alpha
X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying
X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutropenia as add-on to G-CSF. Mavorixafor can enable reductions in G-CSF dosing, which can improve tolerability and is meaningful for patients. FDA has granted priority review for mavorixafor in WHIM, with a PDUFA date of April 30, 2024, and a potential PRV worth $100M upon approval.
2023-11-10 08:00:00 - GlobeNewsWire
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023.
2023-11-09 12:37:01 - Seeking Alpha
X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer Christophe Arbet-Engels – Chief Medical Officer Adam Mostafa – Chief Financial Officer Conference Call Participants Eva Privitera – TD Cowen Stephen Willey – Stifel Edward Tenthoff – Piper Sandler Andy Fleszar – B. Riley Securities Kristen Kluska – Cantor Fitzgerald Swayampakula Ramakanth – H.C.
2023-11-02 08:00:00 - GlobeNewsWire
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and providing corporate updates on Thursday, November 9, 2023.
2023-09-19 08:00:00 - GlobeNewsWire
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.
2023-08-02 08:01:00 - GlobeNewsWire
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the second quarter ended June 30, 2023, and providing corporate and clinical program updates on Thursday, August 10, 2023.
2023-05-06 19:35:09 - Seeking Alpha
X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer Conference Call Participants William Wood - B. Riley Securities Eva Privitera - TD Cowen Swayampakula Ramakanth - Wainwright Rick Miller - Cantor Fitzgerald Operator Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call.
2023-04-26 08:01:00 - GlobeNewsWire
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023.